Net Profit Margin
since 2005
Calculation
Celgene Corp., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss) attributable to Celgene1 | ÷ | Net product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 26.51% | = | 100 | × | 4,046) | ÷ | 15,265) |
| Dec 31, 2017 | 22.66% | = | 100 | × | 2,940) | ÷ | 12,973) |
| Dec 31, 2016 | 17.87% | = | 100 | × | 1,999) | ÷ | 11,185) |
| Dec 31, 2015 | 17.49% | = | 100 | × | 1,602) | ÷ | 9,161) |
| Dec 31, 2014 | 26.44% | = | 100 | × | 2,000) | ÷ | 7,564) |
| Dec 31, 2013 | 22.79% | = | 100 | × | 1,450) | ÷ | 6,362) |
| Dec 31, 2012 | 27.04% | = | 100 | × | 1,456) | ÷ | 5,386) |
| Dec 31, 2011 | 28.05% | = | 100 | × | 1,318) | ÷ | 4,700) |
| Dec 31, 2010 | 25.10% | = | 100 | × | 881) | ÷ | 3,508) |
| Dec 31, 2009 | 30.25% | = | 100 | × | 777) | ÷ | 2,567) |
| Dec 31, 2008 | -71.74% | = | 100 | × | (1,534) | ÷ | 2,138) |
| Dec 31, 2007 | 17.41% | = | 100 | × | 226) | ÷ | 1,300) |
| Dec 31, 2006 | 8.50% | = | 100 | × | 69) | ÷ | 812) |
| Dec 31, 2005 | 14.28% | = | 100 | × | 64) | ÷ | 446) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The analysis of the financial data reveals several noteworthy trends in the company's performance over the fourteen-year period.
- Net Income (Loss) Attributable to Celgene
- Net income demonstrates a generally increasing trend with considerable fluctuations. It begins with moderate positive values from 2005 to 2007, followed by a significant loss in 2008, indicating an exceptional negative event or period that year. From 2009 onwards, net income recovers strongly and shows consistent growth, reaching its highest point in 2018. The recovery phase reflects successful operational or strategic adjustments contributing to profitability.
- Net Product Sales
- Net product sales show robust and continuous growth throughout the entire period. Starting from $446 million in 2005, sales increase steadily each year without interruption, reaching $15.265 billion by 2018. This consistent expansion indicates a strong market demand for the company’s products and effective sales strategies, underpinning the overall financial health despite the occasional net income setbacks observed.
- Net Profit Margin
- The net profit margin exhibits volatility, particularly around 2008 where it sharply declines into a negative value, aligning with the net income loss that year. After this downturn, the margin improves substantially, stabilizing mostly between roughly 17% and 28% from 2009 onward. The margin’s recovery and subsequent stability imply effective cost management and operational efficiency returning post-2008.
Overall, the data suggest a company that experienced a significant operational challenge or loss in 2008 but subsequently demonstrated strong recovery and growth in both sales and profitability. The consistent increase in net product sales combined with a recovering and stable net profit margin supports a positive outlook on the company's ability to generate sustainable profits over the long term.
Comparison to Competitors
Celgene Corp., net profit margin, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 26.51% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 22.66% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 17.87% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 17.49% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 26.44% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 22.79% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 27.04% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 28.05% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 25.10% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 30.25% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | -71.74% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 17.41% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 8.50% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 14.28% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 26.51% | 19.82% |
| Dec 31, 2017 | 22.66% | 13.06% |
| Dec 31, 2016 | 17.87% | 20.78% |
| Dec 31, 2015 | 17.49% | 21.17% |
| Dec 31, 2014 | 26.44% | 21.24% |
| Dec 31, 2013 | 22.79% | 21.99% |
| Dec 31, 2012 | 27.04% | 18.53% |
| Dec 31, 2011 | 28.05% | 15.70% |
| Dec 31, 2010 | 25.10% | 15.16% |
| Dec 31, 2009 | 30.25% | 25.73% |
| Dec 31, 2008 | -71.74% | 18.17% |
| Dec 31, 2007 | 17.41% | 15.90% |
| Dec 31, 2006 | 8.50% | 22.24% |
| Dec 31, 2005 | 14.28% | 18.33% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., net profit margin, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 26.51% | 9.92% |
| Dec 31, 2017 | 22.66% | 8.05% |
| Dec 31, 2016 | 17.87% | 10.68% |
| Dec 31, 2015 | 17.49% | 11.77% |
| Dec 31, 2014 | 26.44% | 12.15% |
| Dec 31, 2013 | 22.79% | 12.81% |
| Dec 31, 2012 | 27.04% | 11.86% |
| Dec 31, 2011 | 28.05% | 10.50% |
| Dec 31, 2010 | 25.10% | 10.48% |
| Dec 31, 2009 | 30.25% | 15.08% |
| Dec 31, 2008 | -71.74% | 11.35% |
| Dec 31, 2007 | 17.41% | 11.02% |
| Dec 31, 2006 | 8.50% | 13.95% |
| Dec 31, 2005 | 14.28% | 13.38% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).